Enfortumab Vedotin
Enfortumab vedotin active in cisplatin-ineligible muscle-invasive bladder cancer
SAN FRANCISCO — Neoadjuvant treatment with enfortumab vedotin demonstrated promising activity among cisplatin-ineligible patients with muscle-invasive bladder cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.
FDA approves enfortumab vedotin for locally advanced, metastatic urothelial carcinoma
FDA grants priority review to Padcev for advanced urothelial cancer
The FDA granted priority review to two supplemental biologics license applications for enfortumab vedotin-ejfv in the treatment of locally advanced or metastatic urothelial cancer.
Enfortumab vedotin confers benefit ‘across the spectrum’ of advanced urothelial carcinoma
Results of two studies presented at Genitourinary Cancers Symposium showed treatment with enfortumab vedotin-ejfv benefited patients with locally advanced or metastatic urothelial carcinoma previously treated with a PD-1 or PD-L1 inhibitor.
Enfortumab vedotin plus pembrolizumab induces durable responses in metastatic urothelial carcinoma
The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among cisplatin-ineligible patients with metastatic urothelial carcinoma, according to results of the multicohort EV-103 study.
FDA grants breakthrough therapy designation to Padcev regimen for advanced bladder cancer
The FDA granted breakthrough therapy designation to enfortumab vedotin-ejfv in combination with pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible for first-line cisplatin-based chemotherapy, according to a press release from the agent’s manufacturer.